Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

XBRL 30 June 2020 filed with the SEC

September 16, 2020August 16, 2022 Alterity Therapeutics

XBRL 30 June 2020 filed with the SEC

2020

Post navigation

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.

Related Posts

Alterity announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson’s disease clinical trials

February 9, 2021August 16, 2022

Prana Biotechnology Investor Presentation and Audio Recording – Phase 2 HD trial

February 18, 2014August 16, 2022

Alterity Half Year Results and Investor Webcast Notification

February 19, 2021August 16, 2022

Recent Posts

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065